NO20021821L - Natrium-hydrogen utvekslingstype 1 inhibitor krystaller - Google Patents

Natrium-hydrogen utvekslingstype 1 inhibitor krystaller

Info

Publication number
NO20021821L
NO20021821L NO20021821A NO20021821A NO20021821L NO 20021821 L NO20021821 L NO 20021821L NO 20021821 A NO20021821 A NO 20021821A NO 20021821 A NO20021821 A NO 20021821A NO 20021821 L NO20021821 L NO 20021821L
Authority
NO
Norway
Prior art keywords
sodium
inhibitor crystals
exchange type
hydrogen exchange
crystals
Prior art date
Application number
NO20021821A
Other languages
English (en)
Norwegian (no)
Other versions
NO20021821D0 (no
Inventor
Lyle Robinson Brostrom
Terrence Joseph Connolly
Zheng Jane Li
Susan Lee Orrill
Bharat Kiritkumar Shah
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of NO20021821L publication Critical patent/NO20021821L/no
Publication of NO20021821D0 publication Critical patent/NO20021821D0/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Surgery (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Treatment Of Water By Ion Exchange (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20021821A 1999-10-29 2002-04-18 Natrium-hydrogen utvekslingstype 1 inhibitor krystaller NO20021821D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16237499P 1999-10-29 1999-10-29
PCT/IB2000/001460 WO2001030759A2 (en) 1999-10-29 2000-10-09 Sodium-hydrogen exchanger type 1 inhibitor crystals

Publications (2)

Publication Number Publication Date
NO20021821L true NO20021821L (no) 2002-04-18
NO20021821D0 NO20021821D0 (no) 2002-04-18

Family

ID=22585355

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20021821A NO20021821D0 (no) 1999-10-29 2002-04-18 Natrium-hydrogen utvekslingstype 1 inhibitor krystaller

Country Status (44)

Country Link
EP (1) EP1224179B1 (cs)
JP (1) JP2003512455A (cs)
KR (1) KR100464526B1 (cs)
CN (2) CN1205205C (cs)
AP (1) AP2002002493A0 (cs)
AR (1) AR029402A1 (cs)
AT (1) ATE271047T1 (cs)
AU (1) AU778573B2 (cs)
BG (1) BG106729A (cs)
BR (1) BR0015275A (cs)
CA (1) CA2389020A1 (cs)
CO (1) CO5271714A1 (cs)
CZ (1) CZ20021332A3 (cs)
DE (1) DE60012208T2 (cs)
DK (1) DK1224179T3 (cs)
DZ (1) DZ3463A1 (cs)
EA (1) EA004937B1 (cs)
EE (1) EE200200227A (cs)
ES (1) ES2222923T3 (cs)
GE (1) GEP20043222B (cs)
GT (1) GT200000180A (cs)
HK (1) HK1048472B (cs)
HR (1) HRP20020366B1 (cs)
HU (1) HUP0204009A3 (cs)
IL (1) IL148581A0 (cs)
IS (1) IS6302A (cs)
MA (1) MA26840A1 (cs)
MX (1) MXPA02004358A (cs)
NO (1) NO20021821D0 (cs)
NZ (1) NZ517738A (cs)
OA (1) OA12080A (cs)
PA (1) PA8505501A1 (cs)
PE (1) PE20010764A1 (cs)
PL (1) PL354869A1 (cs)
PT (1) PT1224179E (cs)
SI (1) SI1224179T1 (cs)
SK (1) SK5312002A3 (cs)
SV (1) SV2002000209A (cs)
TN (1) TNSN00210A1 (cs)
TR (1) TR200201167T2 (cs)
UA (1) UA72002C2 (cs)
WO (1) WO2001030759A2 (cs)
YU (1) YU31502A (cs)
ZA (1) ZA200203295B (cs)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6441176B1 (en) 1999-10-29 2002-08-27 Pfizer Inc. Method for preparing sodium-hydrogen exchanger type 1 inhibitor
YU51903A (sh) * 2001-01-31 2006-05-25 Pfizer Products Inc. Enolati inhibitora izmene natrijum-vodonik tipa-1
CA2472342A1 (en) * 2002-01-30 2003-08-07 Pfizer Products Inc. Zoniporide mesylate pharmaceutical compositions and processes for improving solubility of zoniporide
MXPA04008646A (es) * 2002-05-02 2004-12-06 Pfizer Prod Inc Tratamiento para la diabetes y complicaciones diabeticas con inhibidores del nhe-1.

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030083004A (ko) * 1998-02-27 2003-10-23 화이자 프로덕츠 인크. 허혈 치료용 ｎ-[(치환된 5원 디아자 이불포화고리)카르보닐] 구아니딘 유도체

Also Published As

Publication number Publication date
WO2001030759A2 (en) 2001-05-03
YU31502A (sh) 2004-12-31
WO2001030759A3 (en) 2001-09-13
EP1224179A2 (en) 2002-07-24
MXPA02004358A (es) 2002-11-07
SK5312002A3 (en) 2003-01-09
HUP0204009A2 (hu) 2003-03-28
JP2003512455A (ja) 2003-04-02
BG106729A (bg) 2002-12-29
NO20021821D0 (no) 2002-04-18
CZ20021332A3 (cs) 2002-10-16
PT1224179E (pt) 2004-10-29
AU7441500A (en) 2001-05-08
IS6302A (is) 2002-03-15
PE20010764A1 (es) 2001-07-23
AR029402A1 (es) 2003-06-25
HUP0204009A3 (en) 2004-07-28
AU778573B2 (en) 2004-12-09
DK1224179T3 (da) 2004-10-25
CN1636991A (zh) 2005-07-13
OA12080A (en) 2003-08-25
CA2389020A1 (en) 2001-05-03
SI1224179T1 (en) 2004-10-31
GT200000180A (es) 2002-04-11
ZA200203295B (en) 2003-06-25
KR20020040918A (ko) 2002-05-30
AP2002002493A0 (en) 2002-06-30
ES2222923T3 (es) 2005-02-16
HRP20020366A2 (en) 2004-02-29
EE200200227A (et) 2003-06-16
DZ3463A1 (fr) 2001-05-03
ATE271047T1 (de) 2004-07-15
CO5271714A1 (es) 2003-04-30
TR200201167T2 (tr) 2002-08-21
MA26840A1 (fr) 2004-12-20
CN1205205C (zh) 2005-06-08
KR100464526B1 (ko) 2005-01-03
BR0015275A (pt) 2002-07-16
EA200200416A1 (ru) 2002-10-31
EP1224179B1 (en) 2004-07-14
IL148581A0 (en) 2002-09-12
DE60012208D1 (de) 2004-08-19
HK1048472B (zh) 2005-09-16
SV2002000209A (es) 2002-07-16
UA72002C2 (en) 2005-01-17
PL354869A1 (en) 2004-03-08
HRP20020366B1 (en) 2005-04-30
PA8505501A1 (es) 2003-09-05
CN1384829A (zh) 2002-12-11
EA004937B1 (ru) 2004-10-28
TNSN00210A1 (fr) 2005-11-10
HK1048472A1 (en) 2003-04-04
GEP20043222B (en) 2004-04-26
NZ517738A (en) 2005-06-24
DE60012208T2 (de) 2005-07-21

Similar Documents

Publication Publication Date Title
AP9901478A0 (en) Compounds for the treatment of ischemia.
NO20006323L (no) Glykopeptid-derivater og farmasöytiske sammensetninger som inneholder disse
BR0110101A (pt) N-acil-sulfonamidas promotoras de apoptose
ATE269312T1 (de) N-(amidinophenyl)-n'-(subst.)-3h-2,4- benzodiazepin-3-on derivative als faktor xa inhibitoren
CA2260337A1 (en) Therapeutic agents
NO992821L (no) Ketobenzamider som calpain-inhibitorer
NO20011023L (no) Arylpiperaziner og anvendelse derav som metalloproteinase inhiberende midler (MMP)
AP2002002458A0 (en) Compounds for the treatment of ischemia.
NO990405L (no) Substituerte N-(indol-2-karbonyl)-glycinamider og derivater som antidiabetiske midler
NO20005454L (no) Nye hydroksyindoler, deres anvendelse som fosfodiesterase 4 inhibitorer og fremgangsmåte for fremstilling derav
NO20005237L (no) Heterocyklisk substituerte amider anvendt som calpain- inhibitorer
AR024138A1 (es) Inhibidores de la proliferacion celular
DK1001930T3 (da) N-hydroxyformamidderivater som inhibitorer af matrix-metalloproteinaser
NO20022558L (no) 4-karboksyamino-2-etyl-1,2,3,4-tetrahydrokinolinkrystall som CETP inhibitor
NO980178L (no) Cyklo-oksygenase-inhibitor og amidin-derivatsalter, fremgangsmåte for fremstilling derav, anvendelse derav som legemidler, og farmasöytiske blandinger inneholdende slike derivater
TR200201128T2 (tr) PDE4 inhibitörleri olarak tetrahidrotiyopiranfitalazinon türevleri.
DE69625505T2 (de) Guanidino proteiase inhibitoren
ATE318810T1 (de) 3-oxadiazol-5-yl-1-aminoalkyl-1h-indolderivate
TR200001909T2 (tr) Matris metaloprotez inhibitörleri.
NO20021821L (no) Natrium-hydrogen utvekslingstype 1 inhibitor krystaller
NO20023951L (no) Arylpiperaziner og arylpiperidiner og deres anvendelse som metalloproteinaseinhiberende midler
AP2002002651A0 (en) Sodium-hydrogen exchanger type 1 inhibitor (nhe-1)
TR200100133T2 (tr) FKBP İnhibitörleri
MXPA04004685A (es) Procedimientos para preparar inhibidores de tipo-1 de intercambiador sodio-hidrogeno.
YU62900A (sh) Postupak za dobijanje inhibitora za tip 1 izmenjivača natrijum-vodonik

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application